We also define DNMT1 as a key player in the epigenetic changes regulated by LSD1, ultimately defining a VDR/LSD1/DNMT1 genomic signature that correlates with clinical outcome of patients with PCa. The gene discussed is VDR; the disease is posterior cortical atrophy.